Coblopasvir

• Description:

  Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection[1].

• Product Name Alternative:

  KW-136

• UNSPSC:

  12352005

• Target:

  HCV; HCV Protease

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/coblopasvir.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C (N[C@H] (C (N1[C@@H] (CCC1) C2=NC (C3=CC=C (C=C3) C4=C5OCOC5=C (C=C4) C6=CNC ([C@H]7N (CCC7) C ([C@H] (C (C) C) NC (OC) =O) =O) =N6) =CN2) =O) C (C) C) OC

• Molecular Formula:

  C41H50N8O8

• Molecular Weight:

  782.88

• References & Citations:

  [1]Gao Y, et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial. Liver Int. 2020;40 (11) :2685-2693.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• CAS Number:

  1312608-46-0